Despite the lack of SP action, the net short position has slowly...

Despite the lack of SP action, the net short position has slowly decreased since July from 2.76% or 3.52m shares to 3.26m or 2.55% as of July 16th. I will note that the decrease is quite small, and it is decreasing at a slower rate than it increased during June (on average). In this period the SP is flat. Acadia is up about 10% since July 1st for comparison but is still -42% YTD compared to NEU's -18%~ YTD fall.

This all seems consistent with waiting for ACAD's Q2 numbers. The market has seen that ACAD has stuck with the numbers consistently since they were announced. Since then the open label extension studies have been published (LILAC 1,2 and LOTUS.

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med - Acadia Pharmaceuticals